Compare Standard Lithium Ltd (SLI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs GeneDx Holdings Corp — how do they compare? Standard Lithium Ltd trades at $1.62 (market cap $398.07M), while GeneDx Holdings Corp trades at $68.37 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 5.1× Standard Lithium Ltd's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 23 Days and GeneDx Holdings Corp for 19 Days on average.
| SLI | WGS | |
|---|---|---|
Market Cap | $398.07M | $2.02B |
Volume | 1,564,155 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $167.51 |
52-Week Low | $1.61 | $34.51 |
Typical Hold Time | 23 Days | 19 Days |
Enterprise Value | $260.98M | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLI trades at $1.625, down 1.52% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -15.55% and no revenue in 2025, but has beaten EPS estimates in recent quarters. Key developments include progress toward a 2026 final investment decision for its Arkansas lithium project and new offtake agreements.
SLI presents high risk with no current revenue and negative cash flow from operations, but significant upside potential exists if its lithium projects advance. The consensus price target of $3.83 implies 136% upside, supported by 100% buy ratings from analysts. Execution risk on project timelines and funding remains the primary concern.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
